PDCD1 and cancer: Despite tremendous success of anti-PD-1/PD-L-1 mAbs as immunotherapeutic agents for treating a variety of cancers, these agents suffer from noticeable drawbacks, indicating the need for other drugs to incorporate in the cancer immunotherapy.